Mikhail Samsonov
R-Pharm · R-Pharm International, LLC · Chief Medical Officer, R-Pharm
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
43
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers
21
PubMed author-name match
Trials
Studies that name Mikhail Samsonov as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 17:55 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07880886 · Goflikicept for Resolution and Prevention of Attacks in Pediatric and Adolescent Patients With Colchicine-Resistant or Colchicine-Intolerant Familial Mediterranean FeverR-Pharm · not yet recruiting · Familial Mediterranean Fever, FMF · study director
- Ph3NCT07670546 · Efficacy and Safety of Olokizumab in Patients With Polymyalgia Rheumatica (PROMISE)R-Pharm International, LLC · active not recruiting · Polymyalgia Rheumatica · study director
- Ph3NCT07625384 · Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's DiseaseR-Pharm International, LLC · not yet recruiting · Still Disease · study director
- Ph1NCT07597668 · A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With ExacerbationsR-Pharm · active not recruiting · Multiple Sclerosis · study director
- Ph2NCT07553988 · A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate CancerR-Pharm International, LLC · active not recruiting · Metastatic Castration-resistant Prostate Cancer · study director
- Ph1NCT07543744 · A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRIR-Pharm · recruiting · Metastatic Colorectal Cancer · study director
- Ph2NCT07517575 · Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic ArthritisR-Pharm International, LLC · recruiting · Juvenile Idiopathic Arthritis · study director
- Ph1NCT07435311 · A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell CarcinomaR-Pharm · completed · Head and Neck Squamous Cell Carcinoma · study director
- Ph3NCT07435324 · A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell CarcinomaR-Pharm · completed · Head and Neck Squamous Cell Carcinoma · study director
- Ph3NCT07386938 · A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast CancerR-Pharm · active not recruiting · Locally Advanced Breast Cancer, Metastatic Breast Cancer · study director
- Ph1NCT07206043 · Pharmacokinetics, Safety and Immunogenicity of RPH-104 at a New Dosage and Different Doses Via Single Subcutaneous and Intravenous Administration in Healthy VolunteersR-Pharm International, LLC · completed · Healthy · study director
- Ph2/Ph3NCT06440746 · Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung DiseasesR-Pharm International, LLC · recruiting · Lung Diseases, Interstitial · study director
- Ph3NCT06320353 · Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin MelanomaR-Pharm · completed · Skin Melanoma · study director
- Ph1NCT06307093 · Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant NeoplasmsR-Pharm · completed · Skin Melanoma, Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma · study director
- N/ANCT05773170 · Efficacy and Safety Evaluation of Refralon®, Concentrate for Solution for Intravenous Injection in Patients With Paroxysmal and Persistent Atrial Fibrillation and FlutterR-Pharm · completed · Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, Atrial Flutter · study director
- Ph3NCT05673902 · Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent PericarditisR-Pharm International, LLC · active not recruiting · Idiopathic Recurrent Pericarditis · study director
- Ph3NCT05432960 · Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)R-Pharm International, LLC · withdrawn · Adult-Onset Still's Disease, AOSD · study director
- N/ANCT05196477 · Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) InfectionR-Pharm · completed · COVID-19 · study director
- Ph2NCT05190991 · Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean FeverR-Pharm International, LLC · recruiting · Familial Mediterranean Fever, FMF · study director
- Ph3NCT05187793 · Study of Efficacy of Different Treatment Regimens of OlokizumabR-Pharm · unknown · COVID-19 · study director
- Ph2NCT05092776 · Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of ColchicineR-Pharm International, LLC · active not recruiting · Familial Mediterranean Fever, FMF · study director
- Ph1/Ph2NCT04760730 · Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19)R-Pharm · completed · COVID-19 · study director
- Ph2/Ph3NCT04692766 · Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent PericarditisR-Pharm International, LLC · completed · Pericarditis · study director
- Ph2NCT04686773 · Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 PreventionR-Pharm · completed · COVID-19 · study director
- Ph1/Ph2NCT04684446 · Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19R-Pharm · completed · COVID-19 · study director
- Ph2/Ph3
- Ph2/Ph3NCT04380519 · Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)R-Pharm International, LLC · completed · COVID-19 · study director
- Ph2NCT04246723 · Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1R-Pharm · completed · Chronic Hepatitis c Genotype 1 · study director
- Ph1NCT04246762 · Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4R-Pharm International, LLC · completed · Rheumatoid Arthritis · study director
- Ph2NCT04067492 · Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Evaluation of RPH-104 Administered at Different Doses to Patients With Acute Gout AttackR-Pharm · terminated · Gout Attack · study director
- Ph3
- Ph1NCT03832426 · A Pharmacokinetic Study of Narlaprevir as a Single Dose or With Ritonavir Combination in Patients With Hepatic Impairment and Healthy Matched VolunteersR-Pharm · completed · Hepatic Impairment · study director
- Ph3NCT03669484 · Comparative Clinical Study of Efficacy and Safety of Remimazolam and Propofol in Patients Undergoing Elective Surgery Under General AnaesthesiaR-Pharm · completed · General Anaesthesia · study director
- Ph3NCT03663374 · Efficacy and Safety Evaluating Study of Odelepran for the Use in Patient With Alcohol DependenceR-Pharm · completed · Alcohol Dependence · study director
- Ph1NCT03659305 · Pharmacokinetic Equivalence and Safety Study of RPH-001 and Avastin®R-Pharm · completed · Healthy · study director
- Ph3NCT03575702 · Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder.R-Pharm · completed · Overactive Bladder · study director
- Ph3NCT03551210 · Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired PneumoniaR-Pharm · completed · Pneumonia, Bacterial · study director
- Ph1NCT03537404 · A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral DrugsR-Pharm · completed · Healthy · study director
- Ph2NCT03485846 · Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1bR-Pharm · completed · Chronic Hepatitis C Genotype 1b · study director
- Ph3NCT03120949 · Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid ArthritisR-Pharm International, LLC · completed · Rheumatoid Arthritis · study director
- Ph3NCT02760433 · Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active DiseaseR-Pharm International, LLC · completed · Rheumatoid Arthritis · study director
- Ph3NCT02760407 · Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active DiseaseR-Pharm International, LLC · completed · Rheumatoid Arthritis · study director
- Ph3NCT02760368 · Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active DiseaseR-Pharm International, LLC · completed · Rheumatoid Arthritis · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 17:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 17:55 UTC. The ranking covers the 200 most relevant of 21 PubMed records, and a shared surname and initials can bring in a namesake. All 21 on PubMed
- Treatment of Idiopathic Recurrent Pericarditis With Goflikicept: Phase II/III Study Results.J Am Coll Cardiol · 202364 citationsRCR 5.6
- Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis.N Engl J Med · 202259 citationsRCR 4.6
- 42 citationsRCR 3.4
- 29 citationsRCR 2.2
- 21 citationsRCR 2.5
- Pharmacokinetics of the New Hepatitis C Virus NS3 Protease Inhibitor Narlaprevir following Single-Dose Use with or without Ritonavir in Patients with Liver Cirrhosis.Antimicrob Agents Chemother · 201614 citationsRCR 0.5
- Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment.Ann Rheum Dis · 202413 citationsRCR 2.6
- Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment Elevation Myocardial Infarction: Secondary End Points From an International, Double-Blind, Randomized, Placebo-Controlled, Phase 2a Study.J Cardiovasc Pharmacol · 20249 citationsRCR 1.0
- On the medicinal efficacy of dietetic therapy in patients with rheumatoid arthritis.Int J Clin Pharmacol Res · 19922 citationsRCR 0.1
- 1 citationsRCR 0.1